Journal
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
Volume 13, Issue 1, Pages -Publisher
WILEY
DOI: 10.1002/wnan.1657
Keywords
DNA origami; gene therapeutic; nonviral delivery vector; structured DNA assemblies; vaccine
Funding
- Army Research Office [W911NF1810436]
- Office of Naval Research [N00014-16-1-2953]
- National Institutes of Health [75N91019D00024, HHSN261200800001E, R01-MH112694, R21-EB026008]
- National Science Foundation [CBET-1729397, CCF-1564025]
- Human Frontier Science Program [RGP0029/2014]
- U.S. Department of Defense (DOD) [W911NF1810436] Funding Source: U.S. Department of Defense (DOD)
Ask authors/readers for more resources
Gene therapeutics show promise in treating genetic diseases and cancer through modulation of gene expression and immune cell activation, but face limitations in toxicity, targeting, and efficiency compared to viral vectors. Structured DNA assemblies fabricated using DNA origami principles offer a new nonviral delivery vector with controllable immunostimulatory properties and low manufacturing cost.
Gene therapeutics including siRNAs, anti-sense oligos, messenger RNAs, and CRISPR ribonucleoprotein complexes offer unmet potential to treat over 7,000 known genetic diseases, as well as cancer, through targeted in vivo modulation of aberrant gene expression and immune cell activation. Compared with viral vectors, nonviral delivery vectors offer controlled immunogenicity and low manufacturing cost, yet suffer from limitations in toxicity, targeting, and transduction efficiency. Structured DNA assemblies fabricated using the principle of scaffolded DNA origami offer a new nonviral delivery vector with intrinsic, yet controllable immunostimulatory properties and virus-like spatial presentation of ligands and immunogens for cell-specific targeting, activation, and control over intracellular trafficking, in addition to low manufacturing cost. However, the relative utilities and limitations of these vectors must clearly be demonstrated in preclinical studies for their clinical potential to be realized. Here, we review the major capabilities, opportunities, and challenges we foresee in translating these next-generation delivery and vaccine vectors to the clinic. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology-Inspired Nanomaterials > Nucleic Acid-Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available